Daily Trades
- Dylan Jovine
We’ve had such outrageous gains this year, it’s time to sell off some losers that just haven’t delivered the wins I hoped.
- Dylan Jovine
Lots to discuss today, so I’m going to take them one at a time.
- Dylan Jovine
I recommend selling half your shares in Agios Pharmaceuticals (SYM: AGIO) here at $47.50, a 65% gain from our recommended price of $28.68.
- Dylan Jovine
A lot of folks have been writing in to ask about Agios Pharmaceuticals (SYM: AGIO).
- Dylan Jovine
I first started following Agios Pharmaceuticals (SYM: AGIO) in 2018.
- Dylan Jovine
Investors may want to keep an eye on the red-hot pharmaceutical sector. For one, the sector is still one of the safest, most recession-proof investments around.
deal of the month
Categories
Dylan Jovine | Inside the U.S.- China Trade Reset Under Scott Bessent
Dylan Jovine | The $2 Stock Backed by Palantir That Could Ride a $40 Billion Boom
Dylan Jovine | Market Rally or Bear Trap? Why I’m Staying Realistic Despite the Bounce
Recent posts
Tags
Connect with Us
- Dylan Jovine
We’ve had such outrageous gains this year, it’s time to sell off some losers that just haven’t delivered the wins I hoped.
- Dylan Jovine
Lots to discuss today, so I’m going to take them one at a time.
- Dylan Jovine
I recommend selling half your shares in Agios Pharmaceuticals (SYM: AGIO) here at $47.50, a 65% gain from our recommended price of $28.68.
- Dylan Jovine
A lot of folks have been writing in to ask about Agios Pharmaceuticals (SYM: AGIO).
- Dylan Jovine
I first started following Agios Pharmaceuticals (SYM: AGIO) in 2018.
- Dylan Jovine
Investors may want to keep an eye on the red-hot pharmaceutical sector. For one, the sector is still one of the safest, most recession-proof investments around.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.